Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress
December 09 2009 - 6:04PM
PR Newswire (US)
Masimo Rainbow SET(R) Acoustic Respiration Rate Monitoring
Generates Significant Interest IRVINE, Calif., Dec. 9
/PRNewswire-FirstCall/ -- Masimo (NASDAQ:MASI), the inventor of
Pulse CO-Oximetry and Measure-Through Motion and Low Perfusion
pulse oximetry, announced today that it has received the
prestigious Zenith Award for equipment and service excellence from
the American Association of Respiratory Care (AARC) at their 55th
Annual AARC International Congress in San Antonio, Texas. Masimo
Rainbow SET Acoustic Monitoring was also featured in live
demonstrations at the Masimo commercial exhibit and received very
favorable reviews from respiratory therapists. For the second year
in a row, Masimo has achieved AARC's top industry recognition
honoring respiratory care equipment and pharmaceutical
manufacturers for quality and service excellence. More than 400
companies were eligible for one of five Zenith Award honors. Award
winners are chosen by the association's membership--more than
44,000 respiratory care professionals--based upon the quality of
equipment and/or supplies, accessibility and helpfulness of sales
personnel, as well as the company's responsiveness, service record,
truth in advertising, and overall support of the respiratory care
profession. In addition, hundreds of respiratory care professionals
from all over the world were among the first to see live
demonstrations of Masimo Rainbow SET Acoustic Monitoring--providing
noninvasive and continuous respiration rate (RRa(TM)) that is
accurate, easy-to-use, and enhances patient compliance. Masimo
Rainbow SET Acoustic Monitoring may enable earlier detection of
respiratory compromise and patient distress--offering a
breakthrough in patient safety for post-surgical patients on the
general floor. Comments received from respiratory therapists at the
AARC Congress included the following: David Gibson, RRT,
Supervisor, Medical City Dallas Hospital in Dallas, Texas, stated:
"As a caregiver, I appreciate Masimo's commitment to
innovation--they have done it again with their new Acoustic
Respiration Rate Monitoring technology. Finally, there is a
reliable, easy, comfortable, and cost-effective way to monitor
breathing sounds on my patients on the general floor." Jenni Raake,
MBA, RRT, Respiratory Care Coordinator, Cincinnati Children's
Hospital Medical Center, stated: "I see so many uses for Masimo's
Rainbow Acoustic Monitoring, across so many care areas. With the
wireless Masimo Rad-87 monitor, I believe it will be a great
technology for patients needing ambulation. It should also be
perfect for conscious sedation procedures." Abbie Rosenberg, RRT,
RCP in Santa Cruz, California, added: "I believe that Masimo
Acoustic Respiration Rate will help hospitals effectively monitor
and avoid sentinel events in post-surgical patients using patient
controlled analgesic pumps." Joe Kiani, Founder & CEO of
Masimo, stated: "We are honored to receive the Zenith Award. This
recognition is especially gratifying because it comes from the
clinicians who use our products every day. It's also exciting to
see the reactions and hear the positive reviews from respiratory
therapists who saw first-hand demonstrations of Rainbow Acoustic
Monitoring." Michael O'Reilly, MD, Masimo's EVP of Medical Affairs,
stated: "Respiratory care professionals attending the AARC Congress
were truly excited by the introduction of Rainbow SET Acoustic
Monitoring with its ability to monitor the breathing status of
patients, 24/7. Respiratory care professionals are not alone in
their excitement, as all clinicians who care for patients receiving
patient-controlled analgesia for pain management know that sedation
can slow breathing and place patients at considerable risk. For
these patients, early intervention and appropriate treatment could
mean the difference between life and death." About Masimo Masimo
(NASDAQ:MASI) develops innovative monitoring technologies that
significantly improve patient care -- helping solve "unsolvable"
problems. In 1995, the company debuted Measure-Through Motion and
Low Perfusion pulse oximetry, known as Masimo SET®, which virtually
eliminated false alarms and increased pulse oximetry's ability to
detect life-threatening events. More than 100 independent and
objective studies demonstrate Masimo SET provides the most reliable
SpO2 and pulse rate measurements even under the most challenging
clinical conditions, including patient motion and low peripheral
perfusion. In 2005, Masimo introduced Masimo Rainbow SET® Pulse
CO-Oximetry(TM), a breakthrough noninvasive blood constituent
monitoring platform that can measure many blood constituents that
previously required invasive procedures. Masimo Rainbow SET
continuously and noninvasively measures total hemoglobin
(SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), PVI®, and acoustic respiration rate (RRa),
in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion
index (PI), allowing early detection and treatment of potentially
life-threatening conditions. Founded in 1989, Masimo has the
mission of "Improving Patient Outcomes and Reducing Cost of Care by
Taking Noninvasive Monitoring to New Sites and Applications."
Additional information about Masimo and its products may be found
at http://www.masimo.com/. Forward Looking Statements This press
release includes forward-looking statements as defined in Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, in connection with the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
based on current expectations about future events affecting us and
are subject to risks and uncertainties, all of which are difficult
to predict and many of which are beyond our control and could cause
our actual results to differ materially and adversely from those
expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
belief that the breakthrough respiration rate monitoring
capabilities of Masimo Rainbow SET Acoustic Monitoring technology
will allow clinicians to detect and treat respiratory compromise
and patient distress earlier, risks related to our belief that
Masimo Rainbow SET Acoustic Monitoring technology will provide
sufficient sensitivity and specificity to measure respiratory rate
in a variety of patients and monitoring conditions, risks related
to our assumptions regarding the commercial timing and availability
of the technology, as well as other factors discussed in the "Risk
Factors" section of our most recent reports filed with the
Securities and Exchange Commission ("SEC"), which may be obtained
for free at the SEC's website at http://www.sec.gov/. Although we
believe that the expectations reflected in our forward-looking
statements are reasonable, we do not know whether our expectations
will prove correct. All forward-looking statements included in this
press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of today's date. We do not undertake any obligation to
update, amend or clarify these forward-looking statements or the
"Risk Factors" contained in our most recent reports filed with the
SEC, whether as a result of new information, future events or
otherwise, except as may be required under the applicable
securities laws. Media Contacts: Dana Banks Masimo Corporation +1
(949) 297-7348 Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring
to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet,
PVI, RRa, Radical-7, Rad-87, Rad-57,Rad-9, Rad-8, Rad-5,Pulse
CO-Oximetry and Pulse CO-Oximeter are trademarks or registered
trademarks of Masimo Corporation. DATASOURCE: Masimo CONTACT: Dana
Banks of Masimo Corporation, +1-949-297-7348 Web Site:
http://www.masimo.com/
Copyright